# Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

> **NCT03430687** · PHASE1 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT03430687
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigators prefer to pursue other studies
- **Last updated:** 2020-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430687, "Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03430687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*